Sonablate® HIFU For Prostate Cancer In New Locations Outside The U.S.
2/17/2011
USHIFU LLC (US HIFU), a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 medical device (Sonablate), announces that HIFU with the Sonablate (Sonablate HIFU) is available to prostate cancer patients for the first time in Brazil at Hospital Nossa Senhora das Gracas in Curitiba, capital city of the ...
Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the first patient received subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze(™ technology (rHuPH20, recombinant human hyaluronidase)...
Neoprobe's Phase 3 Lymphoseek Study Reaches Accrual Goal
2/17/2011
Neoprobe Corporation (NYSE: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced that a multi-center Phase 3 study of Lymphoseek® has enrolled clinical subjects to achieve the minimum analysis goal of 196 lymph nodes, the study's primary accrual objective...
Youth Gone Bald: Hair Loss At 20 Years, Prostate Cancer Link?
2/16/2011
Not one young man actually "enjoys" experiencing a receding hairline, but now, there is a link between who start to lose hair at the age of 20 and the likelihood of developing prostate cancer. Early screening is always recommended, but in particular now for youth gone bald...
New studies on the screening and treatment of genitourinary cancers were released today in advance of the fourth annual Genitourinary Cancers Symposium, being held February 17-19, 2011, at the Orlando World Center Marriott in Orlando, Florida...
First FDA-Approved Cancer Treatment Vaccine Available At Roswell Park
2/16/2011
The nation's first FDA-approved cancer treatment vaccine, Provenge (sipuleucel-T), is being offered for the first time in Western New York at Roswell Park Cancer Institute (RPCI). The vaccine is designed for men with advanced prostate cancer who have limited treatment options and who meet eligibility requirements...
After Beating Leukemia, Patient Strives To Help Others
2/16/2011
By the age of 28, Dana Severson was already an Iraq war veteran, an accomplished clinical engineer, a wife and mother. Days following her daughter Genevieve's first birthday, Severson was faced with a reality that would turn her life upside down. After several weeks of experiencing severe headaches and extreme exhaustion, the young mother was diagnosed with acute myeloid leukemia (AML)...
Radiation Helps Cure Hodgkin's Lymphoma, But Future Cancer Risk A Concern
2/16/2011
Modern treatment for early stage Hodgkin's lymphoma is highly effective, leaving most patients with no evidence of cancer. However, experts differ on the best approach: Is chemotherapy enough or does adding radiation therapy improve the outcome? A systematic review comparing the two approaches found a clear advantage to combined therapy, at least in the short term...
Compound Bilirubin In Blood Reduces Lung Cancer Risk
2/16/2011
A compound in the blood, bilirubin, has been identified to reduce risk of lung cancer, chronic obstructive pulmonary disease and all-cause death, based on a study consisting of half a million adults. Bilirubin (formerly referred to as hematoidin) is the yellow breakdown product of normal heme catabolism. Heme is found in hemoglobin, a principal component of red blood cells...
Common Bone Drugs May Reduce Colon Cancer Risk
2/16/2011
An international team of researchers has found that the use of bisphosphonates - drugs already taken by millions of healthy women to prevent bone-loss - for more than one year was associated with a 50 percent reduction in the risk of postmenopausal colorectal cancer. The results were published this week in the Journal of Clinical Oncology. According to lead researcher Prof. Gad Rennert, M.D., Ph...